Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tat-M2NX
- Development stage
- Preclinical
- Lead developer
- The Ohio State University
- Modality
- Peptides
- Administration
- Intravenous
01
Overview
tat-M2NX is a cell-permeable peptide antagonist of the transient receptor potential melastatin 2 (TRPM2) channel. It is composed of the HIV-1 TAT cell-penetrating peptide sequence fused to a specific inhibitory peptide sequence (M2NX) designed to block TRPM2 activity. TRPM2 is a non-selective cation channel activated by oxidative stress and ADP-ribose, which mediates calcium influx and subsequent neurodegeneration in conditions like ischemic stroke. By blocking TRPM2-mediated signaling, tat-M2NX is designed to mitigate neuronal injury and improve cognitive recovery. Research presented at the International Stroke Conference 2026 indicates that tat-M2NX can rescue hippocampal plasticity and memory deficits in mouse models of stroke, suggesting potential for treating post-stroke cognitive impairment (PSCI).
- Other names
- TAT-M2NXTAT-M-2NXTAT-M 2NX
02
Targets
TRPM2 (Transient receptor potential cation channel subfamily M member 2)
Beyond the preview
Go deeper on tat-M2NX.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tat-M2NX.